Clinical Trials Unit, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Department of Endocrinology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Acta Diabetol. 2021 Jun;58(6):723-733. doi: 10.1007/s00592-020-01627-0. Epub 2021 Feb 5.
A better understanding of the current features of type 1 diabetes mellitus (T1DM)-related interventional clinical trials is important for improving clinical trial designs and identifying neglected research areas. Therefore, this study aimed to comprehensively assess T1DM-related interventional clinical trials registered in the ClinicalTrials.gov database.
In this cross-sectional study, T1DM-related clinical trials registered in the ClinicalTrials.gov database were searched on July 1, 2020. The characteristics of the relevant trials were assessed. PubMed and Google Scholar were used to search for publication statuses of primary completed studies.
Overall, 1,421 T1DM-related interventional clinical trials were identified for analysis. Of those trials, 509 (35.8%) involved children and 912 (64.2%) involved only adults. Overall, 63.2% of trials enrolled < 50 participants and 61.9% were registered after patient recruitment. Most trials were single-centered (66.0%). The proportions of trials with children were higher than those with only adults with respect to the primary purpose of health service or prevention (13.6% vs. 4.8%), intervention of device (30.8% vs. 23.9%), education or lifestyle (28.9% vs. 11.3%), and dietary supplement (5.7% vs. 2.5%) (all P < 0.01). Only 24.0% of trials had available results after primary completion. The 5-year cumulative publication rate after primary trial completion was < 40%.
T1DM-related interventional clinical trials registered in ClinicalTrials.gov were dominated by small single-center studies. Most trials lacked the availability of results and their respective publications. Large multicenter interventional clinical trials on T1DM are needed, and more attention should be paid to improve the publication and dissemination of clinical trials results.
深入了解 1 型糖尿病(T1DM)相关干预性临床试验的现状,对于改进临床试验设计和发现被忽视的研究领域至关重要。因此,本研究旨在全面评估在 ClinicalTrials.gov 数据库中注册的 T1DM 相关干预性临床试验。
在这项横断面研究中,我们于 2020 年 7 月 1 日在 ClinicalTrials.gov 数据库中搜索了 T1DM 相关的临床试验。评估了相关试验的特征。使用 PubMed 和 Google Scholar 搜索了主要完成研究的发表情况。
共确定了 1421 项 T1DM 相关干预性临床试验进行分析。其中,509 项(35.8%)涉及儿童,912 项(64.2%)仅涉及成人。总体而言,63.2%的试验纳入的参与者<50 人,61.9%的试验是在招募患者后注册的。大多数试验为单中心(66.0%)。在健康服务或预防的主要目的(13.6% vs. 4.8%)、设备干预(30.8% vs. 23.9%)、教育或生活方式(28.9% vs. 11.3%)和膳食补充剂(5.7% vs. 2.5%)方面,儿童试验的比例均高于仅成人试验(均 P<0.01)。仅有 24.0%的试验在主要完成后有可用的结果。主要试验完成后 5 年的累积发表率<40%。
ClinicalTrials.gov 中注册的 T1DM 相关干预性临床试验主要由小型单中心研究组成。大多数试验缺乏结果的可用性及其相应的出版物。需要开展更多关于 T1DM 的大型多中心干预性临床试验,并且应更加关注提高临床试验结果的发表和传播。